Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Clinical trial NCT03770000 · COMPLETED
Trial details
- NCT number
- NCT03770000
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-12
- Primary completion
- 2021-05-14
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.